WEBULL
WebtradeDownload

Bruker (BRKR) Shares Just Moved, So What Is Going On?

Simply Wall St · 1d ago

Bruker (BRKR) stock is back in focus after the company expanded its collaboration with Atinary Technologies, pairing Bruker instruments with Atinary’s AI driven Self Driving Lab platforms for automated pharmaceutical and chemical R&D workflows.

See our latest analysis for Bruker.

The Atinary agreement arrives after a busy few weeks for Bruker, with the stock showing a 30.39% 90 day share price return and a 74.74% total shareholder return over the past year. However, longer term total returns have been weaker, suggesting current momentum follows a period of underperformance.

If this kind of AI focused R&D story interests you, it can be useful to see what else is moving in the space through our screener of 42 healthcare AI stocks

After a 74.74% total return over the past year and a 30.39% move in 90 days, Bruker now raises a simple question: Is this the moment to step in, or does patience for a cheaper entry make more sense as the valuation picture unfolds?

Most Popular Narrative: 1.8% Undervalued

Bruker’s latest fair value estimate of $59.75 sits slightly above the recent $58.65 close, which suggests the current price is closely tracking this widely followed narrative.

The analysts have a consensus price target of $59.75 for Bruker based on their expectations of its future earnings growth, profit margins and other risk factors.

In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $4.1 billion, earnings will come to $328.4 million, and it would be trading on a PE ratio of 35.4x, assuming you use a discount rate of 8.2%.

Read the complete narrative. Read the complete narrative.

Curious what has to happen for Bruker to earn that price tag? The narrative leans on a sharp swing from losses to profits plus richer margins. The key financial bridge that connects today’s loss making profile to those future earnings is where the real story sits.

Result: Fair Value of $59.75 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Bruker’s story can quickly change if global research funding remains weak, or if cost cuts cannot offset any sustained softness in orders and backlog.

Find out about the key risks to this Bruker narrative.

Next Steps

If this Bruker story feels finely balanced between promise and risk, take a close look at both sides and decide quickly where you stand using the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Bruker?

Bruker may be front of mind right now, but you do not want to miss other opportunities that could fit your style and strengthen your overall portfolio.

Use the Simply Wall St screener to quickly surface ideas that match how you like to invest. A few focused starting points are below.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.